Browse all Indena’s documents about products, events, company information and so much more.
Go to sectionSorry, our website doesn't support IE11 and older versions
For a better experience try a modern browser:
Milan, 28th April
2022 – Indena’s Meriva®
Curcumin Phytosome® continues to reveal new areas of efficacy for
human wellbeing. New clinical evidences show that Meriva® is an
effective oxidative stress modulator, also in the support of kidney detoxing
and filtering functions.
Such evidence comes from studies which
have been done by important Italian universities, specifically to evaluate the
effectiveness of curcumin Phytosome® (Indena’s Meriva®)
for kidney health support.
Chronic renal disease is an
inflammatory based disorder, and curcumin properties in modulating body
response through its antioxidant properties are well known and scientifically
proven. The mentioned studies showed significant effectiveness of curcumin
Phytosome® in being a natural and safe aid for the support of
healthy kidney functions.
The first, new study, by the
University of Milan[1], focused on chronic kidney disease
(CKD) subjects.Chronic kidney disease (CKD) is a
condition due to the progressive loss of renal function and widely recognized
as one of the most relevant risk factors for developing cardiovascular diseases
(CVDs).
In the pilot study, 24 CKD subjects
and 20 healthy volunteers were recruited.
CKD subjects followed nutritional
counselling and were supplemented with Meriva® for six months. The parameters
evaluated at baseline and after 3–6 months were uremic toxins, metagenomic of gut
microbiota (which, as known, can play a pivotal role in controlling the origin
of systemic inflammatory state and CKD progression) and nutritional,
inflammatory, oxidative status. Curcumin significantly levelled plasma
pro-inflammatory mediators and lipid peroxidation.
Another endpoint regarded gut
microbiota: after 6 months of curcumin supplementation it was observed a more
balanced composition of the intestinal microbial population in CKD subjects
using healthy volunteers as control group. Again, the safety profile of Meriva®
after long-term supplementation was confirmed, as no adverse events were
observed in the supplemented group.
This recent study extended the
condition-of-use “maintaining kidney healthy” previously explored by the
University of Chieti-Pescara[2] which had the aim to
evaluate the supplementation of Meriva® in subjects with temporary
kidney dysfunction (TKd) and increased oxidative stress levels.
In the study held by University of
Chieti-Pescara,subjects followed either standard
management or standard management plusMeriva® supplementation and they were
divided according to macroalbuminuria (AER >300 mg albumin on 24 hours) or
microalbuminuria (AER 30 - 300 mg/day albuminuria), being albuminuria a marker
of TKd.
The clinical evidence showed that albuminuria
decreased in all subjects, with a statistically significant positive effect in
the supplement group compared with controls (P<0.05) due to its antioxidant
properties. Oxidative stress level was high in all TKd subjects at inclusion:
it was significantly positively affected in the supplement group (P<0.05)
after 4 weeks. Most supplemented
subjects at 4 weeks did not experience fatigue, another aspect where TKd impact.
As for safety, compliance and tolerability to Meriva® were good.
"One of our most important and historical ingredient keeps being source
of new potential application in wider fields, as such important studies show –says Antonella Riva, Indena’s Head of Product Innovation and Development– We’re very proud that Meriva® can stillhelp researchers to find natural solutions for conditions where response on oxidative
stress is involved, such are kidney discomforts. We’ll keep collaborating with relevant
research centres to work for human wellbeing, which is part of our
mission”.
Sorry, our website doesn't support IE11 and older versions
For a better experience try a modern browser:
This is a private file, to request the download of this resource, please fullfill the fields below.